Relmada Therapeutics, Inc. (RLMD) — SEC Filings
Relmada Therapeutics, Inc. (RLMD) — 38 SEC filings. Latest: EFFECT (Apr 10, 2026). Includes 22 8-K, 6 10-Q, 5 SC 13G/A.
View Relmada Therapeutics, Inc. on SEC EDGAR
Overview
Relmada Therapeutics, Inc. (RLMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 10, 2026: Relmada Therapeutics, Inc. filed an EFFECT form on April 10, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999999995-26-001136, relates to Act 33 and File No. 333-294885. The effectiveness date was April 9, 2026.
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Relmada Therapeutics, Inc. is neutral.
Filing Type Overview
Relmada Therapeutics, Inc. (RLMD) has filed 1 EFFECT, 22 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of RLMD's 29 recent filings, 3 were flagged as high-risk, 8 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | ($37,517,403) |
| EPS | ($1.16) |
| Debt-to-Equity | N/A |
| Cash Position | $1,384,484 |
| Operating Margin | N/A |
| Total Assets | $14,876,244 |
| Total Debt | N/A |
Industry Context
Relmada Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing treatments for central nervous system disorders. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Recent trends include increased investment in novel therapeutic modalities like psilocybin, alongside a continued focus on unmet medical needs in neurology and psychiatry.
Top Tags
corporate-governance (7) · 8-K (6) · 10-Q (4) · pharmaceuticals (4) · Biotechnology (3) · material-agreement (3) · administrative (3) · regulatory-filing (3) · quarterly-report (3) · filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Effectiveness Date | 2026-04-09 | The date the registration statement became effective. |
| Filing Date | 2026-04-10 | The date the filing was accepted by the SEC. |
| Net Loss | $37,517,403 | for the nine months ended September 30, 2025, a 38.7% improvement from $61,322,218 in 2024 |
| Research and Development Expenses | $18,806,667 | for the nine months ended September 30, 2025, a 46.5% decrease from $35,175,531 in 2024 |
| General and Administrative Expenses | $19,960,421 | for the nine months ended September 30, 2025, a 32.7% decrease from $29,639,951 in 2024 |
| Cash and Cash Equivalents | $1,384,484 | as of September 30, 2025, down from $3,857,026 at December 31, 2024 |
| Short-term Investments | $12,502,040 | as of September 30, 2025, down from $41,052,356 at December 31, 2024 |
| Net Proceeds from Offering | $94,000,000 | raised on November 5, 2025, significantly improving liquidity |
| Purchase Price for Sepranolone | $3,000,000 | paid to Asarina Pharma AB |
| Upfront Payment for NDV-01 | $3,500,000 | paid to Trigone for exclusive worldwide rights |
| Shares Issued for NDV-01 | 3,017,420 | representing 10% of outstanding shares at the time of the agreement |
| Minimum Bid Price | $1.00 | regained compliance with Nasdaq Listing Rule 5550(a)(2) on September 15, 2025 |
| Acquisition Price Per Share | $1.00 | The price Aurorium LLC is paying for each share of Relmada Therapeutics. |
| Total Equity Value | $100 million | The overall valuation of Relmada Therapeutics in the acquisition deal. |
| Revenue | $0 | for the quarter ended June 30, 2025, indicating pre-commercial stage |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Relmada Therapeutics, Inc. (RLMD)?
Relmada Therapeutics, Inc. has 38 recent SEC filings from Jan 2024 to Apr 2026, including 22 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RLMD filings?
Across 38 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 33 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Relmada Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Relmada Therapeutics, Inc. (RLMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Relmada Therapeutics, Inc.?
Key financial highlights from Relmada Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RLMD?
The investment thesis for RLMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Relmada Therapeutics, Inc.?
Executive information for Relmada Therapeutics, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Relmada Therapeutics, Inc. stock?
Of RLMD's 29 assessed filings, 3 were flagged high-risk, 8 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Relmada Therapeutics, Inc.?
Forward guidance and predictions for Relmada Therapeutics, Inc. are extracted from SEC filings as they are enriched.